PHAXIAM Therapeutics S.A. Operating Income

PHAXIAM Therapeutics S.A. (PHXM) currently reports a operating income of $-15M as of December 2023. That compares with $-19M in the prior-year period — up 17.4% year over year. Use the charts on this page to explore PHAXIAM Therapeutics S.A.'s operating income history and peer comparisons.

PHAXIAM Therapeutics S.A.'s operating income increased from $-19M to $-15M — a 17.4% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PHAXIAM Therapeutics S.A. reported $-15M in operating income as of December 2023. That compares with $-19M in the prior-year period — up 17.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-15M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PHAXIAM Therapeutics S.A., and consider following PHXM for alerts when major investors trade the stock.

PHAXIAM Therapeutics S.A. is classified in the Healthcare sector. On operating income, it currently shows $-15M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHXM with unrelated industries.